CHICAGO, June 13 /PRNewswire/ -- The Emergency Nurses Association (ENA) today announced that PDL BioPharma(R) had been named a strategic partner for 2007. As a strategic partner, PDL BioPharma(R) will be the exclusive sponsor for the ENA State Leaders December Orientation and the Emergency Nurses Week, October 7-13, 2007. "We are very pleased to announce this partnership with PDL BioPharma(R)," said Donna Mason, RN, MS, CEN, ENA President. "By partnering with ENA, PDL BioPharma(R) gets a unique opportunity to show their support of the life saving work of emergency nurses across the county." Through this partnership, PDL BioPharma(R) will help finance ongoing educational opportunities, professional networking activities as well as events honoring nurses during emergency nurses week. "As a leader in the discovery, development and manufacturing of innovative therapies for serious or life-threatening illnesses, PDL BioPharma(R) has great respect for the work done by nurses in emergency departments every day," said Jaisim Shah, senior vice president, marketing and business affairs, PDL BioPharma Inc. "Like our ground breaking drugs for short-term hypertension treatment and acute myocardial infarction, these healthcare professionals are saving lives everyday. Through this partnership, we hope to raise the visibility of emergency nurses while showing our appreciation for everything that they do. In the United States and Canada, PDL BioPharma(R) markets several commercial biopharmaceutical products for the hospital setting -- Cardene(R) I.V. (http://www.pdlbiopharma.com/index.cfm?navid=32) for the short-term treatment of hypertension, Retavase(R) (http://www.pdlbiopharma.com/index.cfm?navid=35) for acute myocardial infarction and IV Busulfex(R) (http://www.pdlbiopharma.com/index.cfm?navid=37) (Black Box Warning http://www.pdlbiopharma.com/index.cfm?navid=142) for conditioning prior to a bone marrow transplant in association with chronic myelogenous leukemia. About the Emergency Nurses Association The Emergency Nurses Association (ENA) is the only professional nursing association dedicated to defining the future of emergency nursing and emergency care through advocacy, expertise, innovation, and leadership. Founded in 1970, ENA serves as the voice of more than 32,000 members and their patients through research, publications, professional development, injury prevention, and patient education. Additional information is available at ENA's Web site, at http://www.ena.org. About PDL BioPharma(R) PDL BioPharma(R), Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL's research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit http://www.pdl.com.
SOURCE Emergency Nurses Association